Flonase Generic Launch Blocked; Glaxo Drops Switch Plan
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline has shelved an OTC switch of Flonase nasal steroid as a competitive strategy in favor of litigation to block generics
You may also be interested in...
Clarinex OTC Option “Valuable” In Face Of Competition – Schering-Plough
The option to file an OTC switch application for Rx Clarinex (desloratadine) is an important part of Schering-Plough's strategy for growth, CEO Fred Hassan said during the firm's fiscal 2006 fourth-quarter earnings call Jan. 29
Clarinex OTC Option “Valuable” In Face Of Competition – Schering-Plough
The option to file an OTC switch application for Rx Clarinex (desloratadine) is an important part of Schering-Plough's strategy for growth, CEO Fred Hassan said during the firm's fiscal 2006 fourth-quarter earnings call Jan. 29
Clarinex OTC Option “Valuable” In Face Of Competition – Schering-Plough
The option to file an OTC switch application for Rx Clarinex (desloratadine) is an important part of Schering-Plough's strategy for growth, CEO Fred Hassan said during the firm's fiscal 2006 fourth-quarter earnings call Jan. 29
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: